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Objectives: The development of neointimal hyperplasia with subsequent atherosclerotic deposition has been proposed to
cause most late vein graft failures. Our unit has previously demonstrated that placement of a macroporous, loose-fitting
polyester external stent prevents neointimal thickening in porcine vein grafts, and has been proposed as a therapeutic
strategy to prevent late vein graft failure. To reduce any potential long-term complications of the permanent polyester
stent, a study was undertaken to investigate the effect of a biodegradable external stent on porcine vein graft thickening
at 1 month and to identify its longer term effects at 6 months.
Methods: Bilateral saphenous vein to common carotid artery interposition grafting was performed in Large White pigs
(25-32 kg; n  6 per time course group) according to UK Home Office guidelines. A commercially constructed
loose-fitting 8-mm-diameter polyglactin stent was placed externally around the vein graft on one side, and the
contralateral side remained unstented to serve as control. The external stent was designed to biodegrade and hence
disappear within 90 days. Grafts were left in situ for 1 month in 1 group of animals, and for up to 6 months in the other
group, before explantation. Graft morphometric features were assessed with computer-aided planimetry.
Results: At 1 month the vein grafts fitted with the polyglactin stent demonstrated a statistically significant decrease in
neointimal thickening (0.038 mm; interquartile range [IQR], 0.035-0.039 mm) compared with the unstented control
grafts (0.13 mm; IQR; 0.11-0.19; P  .0012), and also in medial thickening (0.09 mm; IQR, 0.086-0.093) compared
with unsheathed control grafts (0.302 mm; IQR, 0.272-0.414; P .0012). The 6-month polyglactin stented grafts also
demonstrated a statistically significant reduction in neointimal thickening (0.049 mm; IQR, 0.047-0.07; P  .0012)
compared with control grafts (0.178 mm; IQR, 0.164-0.19), and also in medial thickening (0.105 mm; IQR,
0.095-0.143) compared with unstented grafts (0.421 mm; IQR, 0.35-0.44; P  .0012, Mann-Whitney U test).
Conclusion: The loose-fitting biodegradable polyglactin external stent reduces porcine vein graft thickening at 1 month,
which persists in the long term, even after degradation of the stent itself. This effective removal of the stent may therefore
reduce the long-term risks for infection andmechanical complications associated with implanted prosthetic material while
still eliciting the primary objective of preventing graft thickening over the long term. Biodegradable external stents
therefore have potential advantages over permanent stent material in clinical application. (J Vasc Surg 2004;40:
1011-19.)
Clinical Relevance: Arteriovenous bypass graft failure has a huge economic effect on health care resources, and a
devastating effect on the patient. The attenuation of vein wall thickening, with subsequent luminal narrowing and
occlusion, is a major goal in improving the longevity of the venous graft, to reduce secondary percutaneous and surgical
interventions. The biodegradable external stent demonstrated in this study has possible clinical applications in bypass
procedures with autogenous venous tissue, and represents a novel approach to ameliorating the problem of intimal
hyperplasia that plagues these grafts.Autologous saphenous vein has consistently proved to
be the conduit of choice in lower limb arterial reconstruc-
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doi:10.1016/j.jvs.2004.08.047tive surgery.1 However, the effectiveness of saphenous vein
grafts in infragenicular bypass is limited by patency rates
approaching 25% to 55% at 5 years after surgery.2,3 While
10% to 15% of grafts fail as a result of early thrombotic
occlusion and technical failure, the main cause of interme-
diate to late vein graft failure is attributable to progressive
neointimal hyperplasia and medial thickening, with subse-
quent superimposed atherosclerosis.4,5 Many pharmaco-
logic interventions have been proposed to reduce neointi-
mal hyperplasia, but apart from aggressive lipid lowering,6
few have proved consistently successful in ameliorating late
vein graft failure.
Physical methods to reduce vein graft disease have also
been postulated. Use of an external sheath around vein
grafts was first demonstrated by Parsonnet in 1963,7 but
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ficial effect of an external polyester support on reducing
neointimal hyperplasia. At our unit in Bristol, United
Kingdom, we have consistently demonstrated that place-
ment of an external, macroporous, nonrestrictive, polyester
(Dacron) sheath prevents neointima formation and medial
thickening in porcine vein grafts.9 These external sheaths
have also been referred to as stents, despite not being used
to physically keep the vessel lumen open. This beneficial
effect was evident within the first month after surgery, and
continued even up to 6 months after implantation.10 How-
ever, long-term support of vein grafts with polyester may
elicit detrimental foreign body and mechanical complica-
tions often associated with implantation of prosthetic ma-
terial.11,12 Furthermore, neointima formation in vein grafts
occurs within the first month after implantation; thus long-
term support with a prosthetic sheath may not be necessary
or desirable. One possible means of averting these compli-
cations is to use an absorbable external sheath that remains
intact for at least 1 month and then is subsequently biode-
graded. To test this hypothesis, a preliminary study was
performed using a hand-built sheath constructed from a
sheet of biodegradable polyglactin 910 Vicryl mesh (Ethi-
con).13 Polyglactin is a copolymer of glycoside and L-
lactide, which is hydrolysed by macrophages and has a
reported absorption rate of between 60 and 90 days.14,15
This pilot study demonstrates that a loose-fitting biode-
gradable sheath does indeed limit neointima formation in
porcine vein grafts at 1 month after implantation.13 How-
ever, whether this effect is sustained over a more prolonged
period was not determined. To test this approach in the
longer term, we examined the effect of an external polygla-
ctin sheath that had been industrially designed and com-
mercially constructed (Vascutek; Fig 1) on neointima for-
mation in a porcine model of saphenous vein carotid artery
interposition grafting, at 1 and 6 months after implanta-
tion. To make as direct a comparison as possible, the
Fig 1. Top, External polyester sheath. Bottom, Purpose-built
polyglactin sheath from Vascutek Ltd. Both are 8 mm in diameter.
Previous studies have established that the polyester sheath inhibits
saphenous vein graft thickening in the pig model.biodegradable polyglactin stent was designed andmanufac-tured to match the mechanical structure and dimensions of
the original nonabsorable polyester Dacron external stent.
METHODS
Animals. Ethical approval for the study was obtained
from the Internal Review Board of theUniversity of Bristol.
Studies were performed in male Large White Landrace
pigs, initially weighing between 25 and 32 kg. Six animals
per time course group (1-month and 6-month studies)
were used. All animals received humane care according to
the United Kingdom Home Office (Scientific Procedures)
Act of 1986.
Surgical procedure. All animals underwent bilateral
saphenous vein into common carotid artery interposition
grafting, as described.16 In brief, 10-cm segments of long
saphenous vein were harvested with a no-touch technique
from the hind limb of each animal. This was stored in an
iso-osmotic sodium chloride solution (0.9 g/L) containing
2 IU/mL of heparin and 50 g/mL of glyceryltrinitrate at
room temperature (23°C) until needed. Both common
carotid arteries were exposed, and vascular clamps were
applied proximally and distally after intravenous injection
of heparin (2 IU/mL). A 2-cm segment of artery was
excised from each artery, and both cut ends were bevelled
obliquely to 45 degrees. Appropriate lengths of reversed
saphenous vein were similarly bevelled and anastomosed
end-to-end with the arteries, with continuous 7-0 polypro-
pylene sutures (Prolene; Ethicon). A purpose-built, com-
mercially constructed 8-mm-diameter polyglactin mesh
tube (Vascutek) was applied to 1 graft as an external sup-
port, covering both anastomoses and 1 cm of proximal and
distal common carotid artery (referred to as a “stented
graft”). The tube was divided longitudinally along 1 side,
and gently insinuated around the completed graft before
reconstitution of the tube with continuous 5-0 Vicryl su-
ture. Contralateral grafts remained unstented as control
grafts. Use of distal or proximal portions of vein, location of
the external stent (left or right), and order of performing
the grafts were randomized between procedures. Neck and
leg wounds were closed in layers, and the animals recovered
and were fed a normal chow diet.
In the 1-month subset, animals were anesthetised again
after 4 weeks, and the grafts were explanted and pressure-
fixed ex vivo for 10 minutes at 100 mm Hg with 6%
paraformaldehyde in phosphate-buffered saline solution
containing 2% sucrose. The grafts were then post-fixed in
the same solution for 24 hours before being transferred to
phosphate-buffered saline solution and processed for wax
embedding.
In the 6-month subset animals were maintained in
social groups of 2 at the University of Bristol Veterinary
School Farm, in special pens for animals of their size. They
were fed amaintenance diet, and the average weight of each
animal at graft explantation was in excess of 200 kg. Ani-
mals were anesthetised again, and the grafts were explanted
and processed as described for the 1-month subset.
Histologic analysis and immunocytochemistry.
Paraffin-embedded tissue was sectioned transversely at 5
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dewaxed, rehydrated, and mounted on glass slides and
stained with Alcian blue Miller elastic stain, van Gieson
stain, or hematoxylin-eosin. Trichrome staining was carried
out by treating sections with 1% (w/v) brilliant crystal
scarlet (acid red 44) in 1.5% (v/v) acetic acid, followed by
20% (w/v) orange G in 4% (w/v) phosphotungstic acid,
then 1% (w/v) aqueous mantanilo yellow. The resultant
staining gave the following color associations: acidic glycos-
aminoglycans, blue-green; elastin, purple-black; collagen,
yellow; smooth muscle, orange or red; and erythrocytes,
red.
For immunocytochemical staining for endothelial cells
and vascular endothelial growth factor (VEGF), sections were
dewaxed, rehydrated, and treated with hydrogen peroxide in
methanol to remove endogenous peroxidase, and sections
were treated with horse serum diluted 1:3 with Tris-buffered
saline solution (pH7.4), drained, and incubatedwith relevant
antibodies overnight at 4oC. For lectin staining (index of
endothelial cells), sections were incubated with horse serum
diluted 1:3 with 20mmol/L ofN-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid (HEPES buffer; pH 7.5), drained
and incubated overnight at 4oC with biotinylated anti-Griffo-
nia simplicifolia, lectin 1 isolectin B4 diluted to 15 mg/mL
with 20 mmol/L of HEPES buffer (pH 7.5; Vector Labora-
tories). For VEGF, sections were treated as for lectin, but
incubated or with goat polyclonal antibody, anti-VEGF (R&
D Systems), diluted to 10 g/mL with 20 mmol/L of
HEPES buffer (pH 7.5). After incubation with primary anti-
bodies, sections were washed with Tris-buffered saline solu-
tion and treated with 1:400 biotinylated goat anti-mouse
immunoglobulin, and then with streptavidin-biotin complex
and horseradish peroxidase (Strept/ABC/HRPO; Dako).
Visualisation was achieved with 3,3=-diaminobenzidine; then,
after counterstaining with diluted hematoxylin, sections were
dehydrated and mounted.
Morphometric analysis. Vessel wall dimensions were
measured with computer-aided planimetry with an Olym-
pus BH-2microscope with a color video camera system and
Microscale TM/TC image analysis system (Digithurst
Ltd).
The area enclosed by the endothelium and the internal
elastic lamina defined the intima, and the area between the
internal and external elastic lamina defined the media.
Luminal, intimal, and medial perimeters were computed
with the luminal boundary (minimal circumference), and
internal and external elastic laminae (maximal circumfer-
ence) as delimiters, and mean values were calculated for all
sections from the same graft. Average intimal and medial
thickness, and minimal and maximal circumference were
derived from the perimeter data for 5 sections from each
graft, with the assumption that the sections consisted of
circular profiles, which was valid because the tissues were
fixed at normal perfusion pressures. The cross-sectional
luminal area was also derived from computer-aided plani-
metric analysis of the grafts.
Data analysis and statistics. Data were collated and
analyzed withMicrosoft Excel software, and nonparametricstatistical analysis was carried out with Statview software
and Instat Graphpad software. Median and interquartile
range (IQR; 25th-75th percentiles) were used as summary
measures, and data were treated nonparametrically. Com-
parison of median values in the groups was performed with
the Mann-Whitney U test for statistical significance.
RESULTS
All grafts in both subsets were patent at explantation,
and showed no evidence of graft infection or aneurysmal
dilatation. At 1 month the biodegradable sheath was still
clearly visible in the outer adventitial region of the grafts,
consistent with the report that it takes up to 90 days to
resorb polyglactin mesh.14,15
Morphometric analysis. Ungrafted porcine saphe-
nous vein harvested at the primary operation was used as a
“zero” baseline, and had no discernible neointima and a
median medial thickness of 0.12 mm (IQR, 0.10-0.14).
At 1 month the vein grafts fitted with the polyglactin
sheath demonstrated a statistically significant decrease in
neointimal thickening (0.038 mm [IQR, 0.035-0.039])
compared with the unstented control grafts (0.13 mm
[IQR; 0.11-0.19]; P .0012), and also in medial thicken-
ing (0.09 mm [IQR, 0.086-0.093) compared with un-
sheathed control grafts (0.302 mm [IQR, 0.272-0.414; P
 .0012; Fig 2). In those grafts left in situ for 6 months a
similar pattern of reduction in neointimal and medial thick-
ening was also demonstrated. Polyglactin stented grafts
showed a statistically significant reduction in neointimal
thickening (0.049 mm [IQR, 0.047-0.07]) in contrast to
control grafts (0.178 mm [IQR. 0.164-0.19; P  .0012)
and also in medial thickening (0.105 mm [IQR, 0.095-
0.143]) compared with unstented grafts (0.421 mm [IQR,
0.35-0.44]; P  .0012; Figs 3 and 4).
At 1 month polyglactin stented vein grafts demon-
strated a statistically significant larger cross-sectional area
(22.802 mm2 [IQR, 4.513-4.562]) in contrast to un-
Fig 2. Planimeteric analysis at 1 month of porcine saphenous vein
grafts fitted with polyglactin external sheaths (n 6). Difference in
thickness between unstented and stented vein grafts statistically
significant for both neointimal and medial thickness. P  .0012,
Mann-Whitney U test. *Statistically significant reduction in thick-
ness.stented control grafts (9.820 mm2 [IQR, 2.633-4.026; P
thickness.
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strated a significantly larger luminal area in the stented
grafts (29.532 mm2 [IQR, 11.113-6.483]) when com-
pared with unstented grafts (19.266 mm2 [IQR, 4.258-
5.497; P  .0004).
In the 6-month subset of grafts the minimal circumfer-
ence measured in the stented grafts (19.345 mm [IQR,
3.577-6.848]) was statistically greater than that measured
in the unstented grafts (15.015 mm [IQR, 2.26-2.49; P
.0001). However, the difference in the maximal circumfer-
ence did not reach statistical significance between the
stented grafts (20.145 mm [IQR, 2.335-8.264]) and the
control grafts (22.640 mm [IQR, 0.979-0.915]; P 
.0767).
Histologic analysis. Immunocytochemical studies of
both subsets of grafts, 1 month and 6 months, indicated
that the space between graft and sheath had become orga-
nized into a thickened neoadventitia containing numerous
sin–stained transverse sections of unsheathed graft 1
r implantation (b), unsheathed graft 6 months after
n (d). Large arrow, External elastic lamina; small arrow,
cale bar represents 1 mm; magnification 12.5.Fig 3. Planimeteric analysis at 6 months of porcine saphenous
vein grafts fitted with polyglactin external sheaths (n  6). Differ-
ence in thickness between unstented and stented vein grafts statis-
tically significant for both neointimal and medial thickness. P 
.0012,Mann-WhitneyU test. *Statistically significant reduction inFig 4. Representative photomicrographs of hematoxylin-eo
month after implantation (a), sheathed graft 1 month afte
implantation (c), and sheathed graft 6 months after implantatio
internal elastic lamina. L, Lumen; NI, neointima; M, media. S
for
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particularly evident around the sheath itself, and began to
extend through the interstices of the macroporous sheath,
connecting with microvessels within the wall of the graft.
By 6 months this network of microvessels had developed
into a mature and organized “neo–vaso vasorum,” which
extended deep into the intima-media interface. This is in
contrast to the unstented grafts, in which there was sparse
development of microvessels around the adventitial area,
which failed to penetrate deeply into the graft wall (Fig 5).
In the stented grafts the neoadventitia and the stent mate-
rial itself also stained positively for GS lectin, a marker of
endothelial cells, and for VEGF (Fig 6).
Large numbers of giant cells and macrophages were
also associated within and around the sheath, engulfing and
biodegrading the polyglactin material. Trichrome staining
has the advantage of not only clearly delineating different
anatomic structures and connective tissue proteins, but also
demonstrates the presence of collagen and glycosaminogly-
cans. In both the 1-month and 6-month grafts the un-
stented grafts exhibitedmuch denser deposition of collagen
and glycosaminoglycans in the media and neointima, com-
pared with the stented grafts.
DISCUSSION
The present study demonstrates that placement of a
Fig 5. Representative photomicrographs of porcine vein
sheathed graft 1 month after implantation (a), sheathe
month after implantation (c), and unsheathed graft 6 m
media; ADV, adventitia. Scale bar in c represents 250 mpurpose-built biodegradable polyglactin external stent pro-foundly inhibits neointimal and medial thickening in por-
cine vein grafts at 1 and 6 months. The inhibitory effect of
the biodegradable external stent on vein graft thickening
evident at 1 month after graft implantation continued even
after degradation of the stent material, with no regression
and subsequent vessel thickening. Biodegradable external
sheaths, which confer their beneficial effect and then intrin-
sically disappear, could potentially be used clinically to
prevent intimal and medial thickening, hence improving
intermediate and long-term vein graft patency rates after
reconstructive surgery while reducing infective complica-
tions associated with implanted prosthetics.
It is possible that the significant reduction in medial
thickening of the porcine vein grafts may lead to long-term
aneurysm formation, as a result of lack of adaptive arterial-
ization, and hence weakness of the graft wall. However, it is
possible that development of the thickened, highly vascular
neoadventitia between the stent and the graft actually
strengthens the graft wall overall. Furthermore, by 6
months the peri-stent fibroplasia observed may lend struc-
tural support to the vein graft. This in turn would compen-
sate for the reduction in medial and intimal thickening,
thereby reducing the risk of aneurysm formation. The data
also suggest that, though the stented vein graft has a
thinner media and intimal layer, the maximal measured
circumference at the external elastic lamina of the vein graft
s demonstrate different degrees of microvessel density in
ft 6 months after implantation (b), unsheathed graft 1
s after implantation (d). L, Lumen; NI, neointima; M,
all slides; magnification 40.graft
d gra
onthis not significantly different from that in the unstented
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adaptation to the arterial circulation. Thus at 6 months the
stented grafts have a significantly larger cross-sectional lu-
minal area and thinner media, but have not become aneu-
rismal, compared with the unstented control grafts. Put
another way, the stented vein graft has still undergone
arterial remodeling, but the wall thickening occurs at the
periphery of the graft, that is, at the neoadventitia and not
in the juxtaluminal region. Further studies of the polygla-
ctin external stent over the longer term would be required
to ultimately determine whether aneurysm formation does
occur.
The beneficial effects of the biodegradable sheath used
in this study are similar to those seen in longer term studies
using the polyester sheath.10 The sheath designed and
Fig 6. Representative photomicrographs of histocytochemical
staining (brown) for lectin (a) and vascular endothelial growth
factor (b) in microvessels in neoadventitial region of sheathed vein
grafts 1 month after implantation, which indicates presence of
endothelial cells lining microvessels and active angiogenesis. Note:
blood cells filling microvessels (black arrow) and smooth muscle
cells surrounding endothelial cells (white arrow) indicate that
genuine arterioles have developed. Scale bar in a represents 50 m
for both slides; magnification 200.constructed by Vascutek Ltd. was similar to the originalpolyester sheath in that, though it was constructed from
polyglactin mesh, it was 8 mm in diameter, macroporous,
and fairly rigid, as maintained by a biodegradable spiral
support. These physical properties are believed to be im-
portant in the capacity of the sheath to attenuate vessel
wall thickening.17 The degree of reduction in intimal and
medial thickening demonstrated in this experiment was
comparable to previous studies using the nonabsorbable
polyester external stent, which also demonstrated neovas-
cualrization and inflammatory cell accumulation in the
neoadventitia.10,17 The present study again points to an-
giogenesis as fundamental to the mechanism underlying
these effects. Stimulation of angiogenesis and promotion of
new vessel growth is widely recognized as a crucial area of
research in the treatment of both peripheral arterial occlu-
sive disease and aortocoronary disease.18 Clinical trials are
currently under way using gene transfer of VEGF and other
vascular growth factors to treat both primary cardiovascular
and peripheral vascular disease, as to prevent graft disease
and recurrent stenosis after intervention.19
The polyglactin stent was associated with a profound
network of microvessels, which, though seen at 1 month,
were particularly evident at 6 months after implantation.
The microvessel network was close to the medial region of
the graft, and extended outward beyond the stent. These
microvessels were filled with blood cells, indicating that this
was in fact a mature neo–vasa vasorum that had been
integrated into the circulatory system. Although microves-
sels were also seen in the adventitial region of the unstented
vein grafts, they were far less numerous and were located
farther from the medial region of the graft. It has previously
been proposed that this proangiogenic effect of the external
stent is axiomatic to its mode of action,9 because the
integrity of a vasa vasorumwould obviate hypoxia, which in
itself is thought to promote vein graft disease and thicken-
ing.20,21 Two mechanisms have been suggested.
First, the loose-fitting external stent enables formation
of a neoadventitia and a neo–vasa vasorum in the space
between the stent and the graft, the initial diameter of the
graft being 5 mm and the stent being 8 mm. Restrictive
external stents actually increase neointimal thickening of
vein grafts,22,23 possibly by obstructing the adventitial vasa
vasorum and reducing microvessel development, thus cas-
ing graft hypoxia.24,25 The loose-fitting stent effectively
confines the neoadventitia so that as it develops the mi-
crovessels are close to the graft itself. It also exemplifies the
necessity of the external stent to be loose fitting for it to
exert its inhibitory effect on vein graft thickening. Restric-
tive biodegradable external supports minimize endothelial
injury26 and prevent edema, cellular disorganization, and
neutrophil accumulation, but ultimately do not prevent
intimal hyperplasia.27-29 Second, the polyglactin material
was associated with infiltration of large numbers of immune
and inflammatory cells. As with any other prosthetic mate-
rial, polyglactin is inflammogenic, and therefore it is not
surprising that the material attracts inflammatory and
phagocytic cells such as monocytes, macrophages, and gi-
ant cells.30,31 These cells accumulate in and around the
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responsible for hydrolyzation and biodegradation of the
material (Fig 7). Although seemingly paradoxical, this re-
sponse may also contribute to the positive effect of the
external stent. These cells release a battery of potent bioac-
tive substances, including cytokines, chemokines, growth
factors, and angiogenic factors,32 which influence vascular
smooth muscle cell proliferation and migration, and angio-
genesis. Thus we propose that the presence of the high
concentration of inflammatory cells in and around the stent
material initiates and promotes microvessel development in
the neoadventitial area. This is further supported by the
dense staining for VEGF, a potent angiogenic factor33 in
and around the sheath area that mirrors the distribution of
staining for lectin, a marker for endothelial cells. Similar
revascularization secondary to inflammatory cell accumula-
tion has been observed after implantation of biodegradable
disks in mice.34,35 However, although the intense inflam-
matory response generated by the biodegradation of the
polyglactin stent is believed to be axiomatic to the process
of neovascularization, it also results in a peri-stent fibrotic
reaction of the surrounding tissues, which made dissection
of the vessels more difficult.
In clinical practice, prosthetic graft complications
are extremely debilitating to the patient and financially
costly to health services.36 The effective removal of the
biodegradable external sheath may therefore reduce the
long-term risks for infection, chronic inflammation, and
mechanical complications associated with implanted pros-
thetic material12,13 while still eliciting the primary objective
of preventing vein graft thickening over the long term.
Biodegradable materials are associated with a lower inci-
dence of surgical wound infection.37-39 There are other
potential clinical applications for the biodegradable exter-
nal sheath. Its use to develop hybrid tissue-prosthetic grafts
Fig 7. Photomicrograph of externally stented porcine vein graft 1
month after implantation demonstrates a multilobed giant cell
(arrows) with dark blue nuclei associated with remnants of poly-
glactin material. Scale bar represents 50 m; magnification 400.has been investigated,40 and it could be used as a means todeliver drugs (eg, paclitaxel, sirolimus), which would have
an additive effect to the sheath itself in attenuating vein
graft thickening. The loose-fitting, macroporous polygla-
ctin biodegradable external sheath may therefore be a safer
and more clinically appropriate prosthesis for use in periph-
eral artery reconstructive surgery.
We thank Dr Tim Ashton and Dr Roshan Maini, Vas-
cutek Ltd, Glasgow, Scotland.
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Dr Michael S. Conte (Boston, Mass). The authors’ labora-
tory has a well-established track record of studying mechanisms of
vein graft disease. They and others have examined this concept of
using an external stent to alter vein graft remodeling, and here they
report on a novel biodegradable mesh support in their well-
characterized pig model. The adaptation of a vein graft to the
arterial circulation is complex, and it’s still only partially under-
stood. After implantation, we know all vein grafts must develop
some increased wall thickness to reduce wall tension. This is a
biomechanical stabilization that is not necessarily pathologic. The
critical question remains, what differentiates grafts that achieve
stable arterialization from those that develop stenosis?
External stenting of the vein might change remodeling by
providing mechanical support, reducing dilatation, and reducing
wall tension, or perhaps might affect the role of the adventitia,
which is increasingly of interest in the setting of arterial angioplasty
and also in vein grafting. My questions focus on the interpretation
of the results and the potential mechanisms. You reported reduc-
tions in wall thickness that were significant. However, the stent
might also restrict outward remodeling of the vein, which may be
adaptive. Accordingly, can you tell us if there are any actual
differences in lumen size or total external vessel size between the
groups, and if the radius–to–wall thickness ratio, which is a mea-
sure of vein graft remodeling, was different.
Your studies also suggest that you’ve essentially created a new,
thickened neoadventitia, and perhaps it’s more relevant to measurelooking at the overall effect on the vein graft in terms of interpret-
ing these results.
In this or previous studies, have you actually examined the
cellular kinetics in the wall of stented grafts to elucidate any
changes in cell proliferation, cell death, or cell density?
And finally, in many settings increased inflammation leads to
increased fibrosis, which is likely deleterious. Can you conjecture
why increased inflammation secondary to the prosthetic might
actually be of benefit in this setting.
Dr Vikram Vijayan. The external stents used in this study
were all non-restrictive, and thus did not hamper initial distention
of the vein graft on implantation into the high-pressure arterial
system. We believe this is of paramount importance, because it
enables development of the highly vascular, thickened, neoadven-
titia between the graft wall and stent, which we believe allows the
sheath to offload the normal deformational forces the graft is
subjected to, and reduces hypoxia and oxygen stress as a stimulus
for intimal hyperplasia. We have recently acquired further data
regarding cross-sectional luminal area, and I can confirm that in
both 1-month and 6-month grafts the luminal area is statistically
greater in the stented grafts compared with the unstented control
grafts. The data also suggest that the maximal accurately measured
circumference of both the stented and unstented grafts at 6
months was not significantly different, which indicates that the
grafts were approximately of similar size.
It was not feasible to accurately measure the thickness of the
neoadventitia, because of the degree of peri-sheath fibrosis and the
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 5 Vijayan et al 1019actual inflammatory process of biodegradation. Only sparse frag-
ments of sheathmaterial could be visualized in the 6-month group,
and the neoadventitia had by this time become incorporated into
the dense fibrotic tissue surrounding the graft. I concede that it
would have been more relevant to include neoadventitial thicken-
ing in our results, but any attempt to measure this layer would thus
be arbitrary and inaccurate, and hence our data reflect only those
vein wall layers that could be accurately measured with computer-
aided planimetry.
We do not have any data on cellular kinetics from this partic-
ular study, but in a 1-month pilot study using a similar polyglactin
external stent, cells within the stent displayed a high degree of
proliferating cell nuclear antigen positivity, indicating active pro-
liferative processes, most likely angiogenesis, occurring within the
stent. Previous experiments using the nonabsorbable polyester
stent also indicated less cellular proliferation at the neointimal andmedial layer of stented grafts, which suggests that the reduction in
vein wall thickening is due to reduced cellular proliferation, as
apposed to increased apoptosis.
The process of biodegradation does indeed produce a local-
ized inflammatory reaction around the stent, causing peri-stent
fibroplasias, but we believe this inflammation is axiomatic in the
underlying mechanism of the stent. There is evidence in the
literature on how biodegradable materials, such as polyglactin,
initiate endotheliazation through the macrophages and immune
cells associated with the process of biodegradation. These cells
release a battery of bioactive cytokines, such as vascular endothelial
growth factor and platelet-derived growth factor, which we believe
stimulates the process of inflammation and angiogenesis around
the stent, thus developing the thickened neoadventitia at the
periphery of the graft and improving graft wall oxygenation and
reducing hypoxic stress.
